GlassScriptPhysician profile
Shannon T Barton
NPI 1295738722
$12,928.20
in general payments reported to CMS, 2019-2025
60 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,402 · 2020: $1,926 · 2021: $2,215 · 2022: $1,657 · 2023: $2,267 · 2024: $2,073 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,716 · Education: $12.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,715.83 |
| Education | $12.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,235.76 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,110.53 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $975.34 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $968.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corium, LLC | $708.26 | 2022-2025 | Azstarys, Azstarys |
| Amgen INC. | $658.15 | 2019-2024 | Otezla, Repatha |
| Pfizer INC. | $595.81 | 2019-2025 | |
| Glaxosmithkline, LLC. | $440.03 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $402.31 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Allergan, INC. | $380.21 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $366.65 | 2021-2025 | |
| Axsome Therapeutics, INC. | $351.20 | 2023-2025 | Sunosi, Auvelity |
| Janssen Pharmaceuticals, INC | $333.26 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $324.68 | 2023-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $301.25 | 2019-2024 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $239.11 | 2020-2025 | Trintellix |
| Tris Pharma INC | $208.18 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $198.06 | 2022-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $197.82 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.07 | 2021-2024 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $182.84 | 2022 | |
| Lundbeck LLC | $177.18 | 2024-2025 | Rexulti, Brintellix |
| Dexcom, INC. | $173.66 | 2022-2025 | Dexcom G6 Transmitter |
| Collegium Pharmaceutical, INC. | $172.07 | 2023-2025 | Belbuca, Xtampza, Jornay Pm |
| Bausch Health US, LLC | $151.55 | 2019-2021 | |
| Astellas Pharma US INC | $148.82 | 2019-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $144.84 | 2019-2024 | Belsomra, Verquvo, Gardasil |
| E.R. Squibb & Sons, L.L.C. | $144.20 | 2019-2025 | Cobenfy, Eliquis |
| Teva Pharmaceuticals USA, INC. | $121.42 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $120.32 | 2020-2023 | Mitigare, Ryaltris |
| Exact Sciences Corporation | $111.46 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $99.76 | 2020-2021 | |
| Amarin Pharma, INC. | $84.65 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $73.09 | 2022-2024 | |
| Corcept Therapeutics | $72.93 | 2019-2025 | Korlym |
| Abbott Laboratories | $72.20 | 2022-2025 | Freestyle Libre 3 |
| Eyevance Pharmaceuticals LLC | $63.85 | 2021 | |
| Sunovion Pharmaceuticals INC. | $62.34 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $56.44 | 2021 | |
| Idorsia Pharmaceuticals US INC | $46.67 | 2023-2024 | Quviviq |
| Mylan Specialty L.P. | $44.61 | 2022-2023 | Yupelri |
| Sumitomo Pharma America, INC. | $41.24 | 2023 | Gemtesa |
| Alkermes, INC. | $32.48 | 2023 | Aristada, Lybalvi |
| Grifols USA, LLC | $30.79 | 2019-2020 | |
| Halozyme INC | $27.74 | 2023 | |
| Phadia US INC. | $26.96 | 2020-2021 | |
| Vital Connect, INC | $26.93 | 2025 | Vitalpatch Rtm |
| Noven Therapeutics, LLC | $23.53 | 2023 | Xelstrym |
| Cranial Technologies, INC | $20.95 | 2019 | |
| Supernus Pharmaceuticals, INC. | $20.41 | 2021 | Tlando, Xyosted |
| Jazz Pharmaceuticals INC. | $20.21 | 2021 | |
| Atland Pharmaceuticals, LLC | $20.20 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Horizon Therapeutics Plc | $19.23 | 2021 | |
| Adlon Therapeutics L.P. | $17.44 | 2021 | |
| Currax Pharmaceuticals LLC | $16.42 | 2022 | |
| Ironwood Pharmaceuticals, INC | $16.17 | 2020 | |
| Antares Pharma, INC. | $14.95 | 2024 | Xyosted |
| Cequr Corporation | $12.58 | 2022 | |
| Sanofi Pasteur INC. | $12.42 | 2021 | |
| Amneal Pharmaceuticals LLC | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.